lobbying_activities: 1915914

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
1915914	12432f87-3c38-4bd8-bac4-0e97f0cbe9d1	Q4	PRIME THERAPEUTICS	400339576	PRIME THERAPEUTICS	2016	fourth_quarter	PHA	H.R.4784: Lower Drug Costs Through Competition Act, support increasing generic availability. S.2680: A bill to amend the Public Health Service Act to provide comprehensive mental health reform, and for other purposes. S.2615: the Increasing Competition in Pharmaceuticals Act.	HOUSE OF REPRESENTATIVES,SENATE		50000	0	0	2017-01-17T16:00:42-05:00